Management of immunocompromised patients with evidence of an invasive mycosis

T. J. Walsh

Research output: Contribution to journalReview articlepeer-review

Abstract

Invasive fungal infections have emerged as major causes of morbidity and mortality in immunocompromised patients, particularly granulocytopenic and HIV-infected hosts. Diagnosis and treatment of these infections is determined by the type of fungus and the sites of infection. While Candida spp. and Aspergillus spp. are the most common causes of fungal infection in granulocytopenic patients, less common pathogens are emerging as new challenges. This article summarizes current approaches used in the National Cancer Institute's Pediatric Branch for management of invasive fungal infections.

Original languageEnglish (US)
Pages (from-to)1003-1026
Number of pages24
JournalHematology/Oncology Clinics of North America
Volume7
Issue number5
StatePublished - Oct 12 1993

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Management of immunocompromised patients with evidence of an invasive mycosis'. Together they form a unique fingerprint.

Cite this